Grzegorz Borowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Grzegorz Borowski has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Maria Zasadzińska
Independent Public Specialist Western Hospital John Paul II in Grodzisk Mazowiecki, Poland
2 shared publications Adam Mróz
Zakład Medycyny Społecznej i Zdrowia Publicznego, Warszawski Uniwersytet Medyczny, Warszawa, Polska
1 shared publication- Agnieszka Kluczna
Department of Palliative Medicine, Institute of Sciences, University of Opole, 45-052 Opole, Poland
1 shared publication Julia Załęcka
Instytut Nauk Medycznych Uniwersytet Opolski, Opole, Polska
1 shared publication- Tomasz Dzierżanowski
Laboratory of Palliative Medicine, Department of Social Medicine and Public Health, Medical University of Warsaw, 02-007 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 31 March 2025
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 94 (1) , e1219
Semaglutide as a promising treatment for metabolic dysfunction‑associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder globally, and if left untreated, it may progress to liver cirrhosis and even hepatocellular carcinoma. As of 2024, the European Association for the Study of the Liver Guidelines have recommended resmetirom as the only pharmacological treatment for adults with non-cirrhotic MASLD who have significant fibrosis (stage ≥2). However, lifestyle interventions and management of comorbidities, such as type 2 diabetes and obesity, remain the cornerstone of treatment. Glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown emerging promise in treating MASLD. Notably, the Phase III ESSENCE trial, presented in late 2024, demonstrated semaglutide's potential in improving liver fibrosis, confirmed through histological evaluation, marking a possible breakthrough for MASLD management. This review aims to synthesise current evidence on the efficacy of semaglutide in treating MASLD, highlighting its potential to fill a significant gap in the therapeutic options available for this growing global health concern.
- 31 March 2025
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 94 (1) , e1219
Open AccessSemaglutide as a promising treatment for metabolic dysfunction‑associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder globally, and if left untreated, it may progress to liver cirrhosis and even hepatocellular carcinoma. As of 2024, the European Association for the Study of the Liver Guidelines have recommended resmetirom as the only pharmacological treatment for adults with non-cirrhotic MASLD who have significant fibrosis (stage ≥2). However, lifestyle interventions and management of comorbidities, such as type 2 diabetes and obesity, remain the cornerstone of treatment. Glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown emerging promise in treating MASLD. Notably, the Phase III ESSENCE trial, presented in late 2024, demonstrated semaglutide's potential in improving liver fibrosis, confirmed through histological evaluation, marking a possible breakthrough for MASLD management. This review aims to synthesise current evidence on the efficacy of semaglutide in treating MASLD, highlighting its potential to fill a significant gap in the therapeutic options available for this growing global health concern.
- Open Access
- 1 January 2023
- Published by Termedia Sp. z.o.o. in Palliative Medicine
- Vol. 15 (4) , 167-176
Clinical characteristics and review of current treatment methods for trigeminal neuralgia
Trigeminal neuralgia is one of the most painful conditions a person can experience. Depending on the aetiology, 3 types of neuralgia can be distinguished: classic, secondary, and idiopathic. It can be a challenge in palliative care, especially in patients with multiple sclerosis, in whom...
- 1 January 2023
- Published by Termedia Sp. z.o.o. in Palliative Medicine
- Vol. 15 (4) , 167-176
Open AccessClinical characteristics and review of current treatment methods for trigeminal neuralgia
Trigeminal neuralgia is one of the most painful conditions a person can experience. Depending on the aetiology, 3 types of neuralgia can be distinguished: classic, secondary, and idiopathic. It can be a challenge in palliative care, especially in patients with multiple sclerosis, in whom...